Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
334.7 GBX | -1.56% | -1.69% | +17.42% |
05-14 | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
05-14 | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.42% | 3.68B | |
+33.67% | 709B | |
+30.98% | 595B | |
-2.20% | 367B | |
+20.70% | 334B | |
+5.11% | 289B | |
+14.42% | 239B | |
+9.28% | 211B | |
-3.44% | 203B | |
+8.38% | 171B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : HUTCHMED Limited - Special Call